EHA 2018 | Using MRD to inform CLL treatment in a clinical trial
Achievement of a complete response and measurable residual disease (MRD) negativity are associated with improved survival in chronic lymphocytic leukemia (CLL). Pierre Feugier, MD, PhD, of the Centre Hospitalier Universitaire Régional de Nancy, Vandoeuvre les Nancy, France, presented induction phase results from the ICLL07 FILO study (NCT02666898) at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. This trial investigated how MRD status could be used to guide treatment, with all patients receiving obinutuzumab and ibrutinib, followed by FC chemotherapy when MRD positivity was determined. Complete response rates were quite high, without excess toxicity; however, most patients required subsequent immunochemotherapy owing to low MRD negativity rates.
